Organ‐on‐chip for advancing CAR therapy

Abstract Despite great strides of progress, at least 60% of the responding patients relapse to CAR therapy across the blood malignancies. Off‐tumor toxicity apart from functional deficits, cytopenia and infection are the major unfavourable effect of CAR therapy. Models, which faithfully recapitulate...

Full description

Saved in:
Bibliographic Details
Main Authors: Lightson Ngashangva, Sunil Martin
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Clinical & Translational Immunology
Subjects:
Online Access:https://doi.org/10.1002/cti2.70024
Tags: Add Tag
No Tags, Be the first to tag this record!